# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ada Lovelace (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI031-SYN-TD
- Date: 1851-06-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Whitley-Adeyemi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- She wants to know plainly what the bleeding means and to make her own decisions **S**
- She wants her mornings clear-headed for her mathematical work and fears that stronger pain medicine will cloud her mind **S**

## Your goals

- Average pelvic pain at or below 3 of 10 without daytime sedation. Target: 1851-07-14. Recorded outcome: Average pain 3 of 10 after radiation, on long-acting morphine, without daytime sleepiness. **S**
- Bleeding controlled and hemoglobin above 10 g/dL without transfusion. Target: 1851-09-08. Recorded outcome: No bleeding since radiation; hemoglobin 10.6 g/dL. **S**
- A documented goals-of-care conversation and a named health care agent. Target: 1851-09-08. Recorded outcome: Advance care plan and goals-of-care conversation recorded. **S**
- Able to work on her mathematics for at least two hours most mornings. Target: 1851-10-20. Recorded outcome: Working most mornings. **S**

## What we agreed to do

- Gynecologic oncology consultation in two weeks for a friable cervical mass with bleeding and pain, biopsied today: diagnosis, staging, treatment intent, bleeding control, and pain. Guideline: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Revised FIGO staging for carcinoma of the cervix uteri (Bhatla N, et al. Int J Gynaecol Obstet 2019;145:129-135) (2018) **S**
- Stop opium tincture and change to measured oral morphine solution 5 mg every 4 hours as needed with an oral syringe, with acetaminophen, senna and polyethylene glycol, a naloxone nasal spray, a prescription monitoring check, locked storage, one prescriber, and review in two weeks. Guideline: Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (Dowell D, et al. MMWR Recomm Rep 2022;71(RR-3):1-95) (2022) **S**
- Iron deficiency anemia: ferric carboxymaltose 750 mg intravenously today and in two weeks, with a blood count at each visit and ferritin 6 to 8 weeks after the infusions. Guideline: CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026) **S**
- Blood tests: blood count, ferritin, creatinine, ALT, albumin and a pregnancy test; HIV, hepatitis B and hepatitis C tests before any cancer treatment; PHQ-9. Guideline: Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (Hwang JP, et al. J Clin Oncol 2020;38:3698-3715) (2020); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Staging by FIGO 1843 with pelvic MRI and PET-CT, and a CT-guided biopsy of a lung nodule; tumor PD-L1, mismatch repair and HER2 testing; no germline testing, because cervical cancer is not a hereditary cancer syndrome. Guideline: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Revised FIGO staging for carcinoma of the cervix uteri (Bhatla N, et al. Int J Gynaecol Obstet 2019;145:129-135) (2018) **S**
- Palliative pelvic radiation, 20 Gy in 5 fractions, for bleeding and pain, then carboplatin, paclitaxel and pembrolizumab every 3 weeks for six cycles with pembrolizumab continuing, without bevacizumab while bleeding and after pelvic radiation; blood counts before each cycle and thyroid tests every six weeks. Guideline: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021) **S**
- Specialist palliative care alongside cancer treatment from diagnosis, for pain, symptoms, mood, and goals-of-care conversations, with long-acting morphine 15 mg every 12 hours and oral morphine 5 mg as needed for breakthrough pain. Guideline: Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); Patient-Clinician Communication: ASCO Guideline Update (Gilligan T, et al. J Clin Oncol 2026;44:1040-1057) (2026) **S**

## Follow-up

- 1851-06-02: New patient visit for abnormal bleeding and pelvic pain: history, speculum examination and cervical biopsy, blood count and iron studies, conversion of opium tincture to measured oral morphine, an iron infusion, and a gynecologic oncology referral **S**
- 1851-06-16: Two-week follow-up and gynecologic oncology consultation: pathology, MRI and PET-CT, staging, treatment intent, palliative care, and long-acting morphine **S**
- 1851-07-14: Six-week review: bleeding and pain after palliative pelvic radiation, the first cycle of chemotherapy with pembrolizumab, blood counts, mood and opioid safety **S**
- 1851-08-18: Periodic adult preventive visit **S**
- 1851-09-08: Fourteen-week review: restaging CT, blood counts, iron and thyroid, pain, and a goals-of-care conversation **S**
- 1851-10-20: Twenty-week review after the last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her work **S**

This teaching document does not replace care from a qualified clinician.
